Neuralgene Company Profile
Neuralgene is a biotechnology company with the focus of developing gene therapy for Neurodegenerative disorders. Neuralgene’s main development is PRCN-829, an AAV based gene therapy for the treatment of ALS. This gene therapy targets several key underlying mechanisms of ALS. This therapy is designed to not only target gene delivery to the brain and spinal cord, but also to genetically engineer stem cells. Neuralgene will be working in conjunction with Precision StemCell of Bogota, Colombia. Neuralgene’s gene therapy technology is based off of stem cell work performed by Jason Williams, MD. Dr. Williams determined that stem cells are producing substances that inhibit the process of ALS. The problem with stem cell therapy used alone, though it can be beneficial, it does not seem to have permanent lasting results. This has been shown with several different stem cell treatments in regards to ALS. PRCN-829 was developed to provide the benefits that occur with stem cell therapy, but to amplify and lengthen the effects. The effect of AAV gene therapy last for many years and may actually be lifelong.